Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension trial of maridebart cafraglutide in adults with obesity or overweight
jRCT2031260446Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jul 2026
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
01
Overview
Phase 3, randomised, double-blind trial of maridebart cafraglutide in obesity and Overweight (10 arms), sponsored by Amgen. Primary endpoints: Percent change in body weight from baseline of the parent trial and Treatment-emergent adverse events and serious adverse events. Started Jul 2026; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2031260446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260446.